



## Total Voting Rights

June 3, 2024 2:22 PM EDT

RNS Number : 9173Q  
MaxCyte, Inc.  
03 June 2024

### MaxCyte, Inc.

("MaxCyte" or the "Company")

#### Total Voting Rights and Block Listing Return

**ROCKVILLE, MD, June 3, 2024:** [MaxCyte, Inc.](#), (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, announces that pursuant to its block admission facility, since 29 February 2024 it has issued 298,824 of common stock, \$0.01 par, of the Company ("Common Stock") in satisfaction of the exercise of share options and/or vesting of restricted stock units.

#### Total voting rights

As at 31 March 2024, the total issued stock capital of the Company following the recent issue of the new Common Stock is 104,395,574 shares of Common Stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

#### Block Listing Return

MaxCyte also makes the following notification pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies, regarding its existing block listings:

Name of <i>applicant</i> :		MaxCyte, Inc.			
Name of scheme:		MaxCyte Long Term Incentive Plan			
Period of return:	From:	1 August 2023	To:	31 March 2024	
Balance of unallotted securities under scheme(s) from previous return:		9,929,345 ordinary shares of common stock at \$0.01 each			
<u>Plus:</u> The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		Nil			
<u>Less:</u> Number of <i>securities</i> issued/allotted under scheme(s) during period (see LR3.5.7G):		891,003 ordinary shares of common stock at \$0.01 each			
<u>Equals:</u> Balance under scheme(s) not yet issued/allotted at end of period:		9,038,342 ordinary shares of common stock at \$0.01 each			

Name of contact:	Douglas Swirsky, Chief Financial Officer
Telephone number of contact:	+1 301 944 1700

For further information, please contact:

**MaxCyte Contacts:**

**US IR Adviser**

+1 415-937-5400

**Gilmartin Group**

[ir@maxcyte.com](mailto:ir@maxcyte.com)

David Deuchler, CFA

**Nominated Adviser and Joint Corporate Broker**

Panmure Gordon

+44 (0)20 7886 2500

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

**UK IR Adviser**

+44 (0)203 709 5700

**ICR Consilium**

[maxcyte@consilium-](mailto:maxcyte@consilium-comms.com)

Mary-Jane Elliott

[comms.com](http://comms.com)

Chris Welsh

**About MaxCyte**

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our EXPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The EXPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at [maxcyte.com](http://maxcyte.com) and follow us on [X](#) (formerly Twitter) and [LinkedIn](#).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TVRQKNBBQBKDDAK